176 related articles for article (PubMed ID: 24709418)
1. Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.
Ahsan A; Ramanand SG; Bergin IL; Zhao L; Whitehead CE; Rehemtulla A; Ray D; Pratt WB; Lawrence TS; Nyati MK
Neoplasia; 2014 Feb; 16(2):105-14. PubMed ID: 24709418
[TBL] [Abstract][Full Text] [Related]
2. Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.
Ahsan A; Ray D; Ramanand SG; Hegde A; Whitehead C; Rehemtulla A; Morishima Y; Pratt WB; Osawa Y; Lawrence TS; Nyati MK
J Biol Chem; 2013 Sep; 288(37):26879-86. PubMed ID: 23897823
[TBL] [Abstract][Full Text] [Related]
3. A new gamboge derivative compound 2 inhibits cancer stem-like cells via suppressing EGFR tyrosine phosphorylation in head and neck squamous cell carcinoma.
Deng R; Wang X; Liu Y; Yan M; Hanada S; Xu Q; Zhang J; Han Z; Chen W; Zhang P
J Cell Mol Med; 2013 Nov; 17(11):1422-33. PubMed ID: 24112466
[TBL] [Abstract][Full Text] [Related]
4. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
[TBL] [Abstract][Full Text] [Related]
6. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
7. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
8. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
9. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
Schmitt NC; Trivedi S; Ferris RL
Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
[TBL] [Abstract][Full Text] [Related]
10. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
11. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
[TBL] [Abstract][Full Text] [Related]
12. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
14. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
16. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
17. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery.
Bhirde AA; Patel V; Gavard J; Zhang G; Sousa AA; Masedunskas A; Leapman RD; Weigert R; Gutkind JS; Rusling JF
ACS Nano; 2009 Feb; 3(2):307-16. PubMed ID: 19236065
[TBL] [Abstract][Full Text] [Related]
18. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models.
Thomas SM; Sahu B; Rapireddy S; Bahal R; Wheeler SE; Procopio EM; Kim J; Joyce SC; Contrucci S; Wang Y; Chiosea SI; Lathrop KL; Watkins S; Grandis JR; Armitage BA; Ly DH
ACS Chem Biol; 2013 Feb; 8(2):345-52. PubMed ID: 23113581
[TBL] [Abstract][Full Text] [Related]
20. The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.
Yoshida T; Okamoto I; Iwasa T; Fukuoka M; Nakagawa K
FEBS Lett; 2008 Dec; 582(30):4125-30. PubMed ID: 19027738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
